openPR Logo
Press release

Neuropeptide Y Acetate Market

06-27-2017 12:58 PM CET | Health & Medicine

Press release from: Pharamceutical

Neuropeptide Y (NPY), a peptide with 36-amino acids, acts as a neurotransmitter in the autonomic nervous system (ANS). It is one of the most abundant neuropeptides in the central and peripheral nervous system. In the periphery, NPY is widely distributed in the adrenal medulla, in the sympathetic nerves, platelets, and various cell types within white adipose tissue. NPY in the central nervous systems is found in highest concentration within the brain stem, hypothalamus, and anterior pituitary. In spite of the major improvements and simplifications in peptide synthesis over the last few years, a considerable amount of skill is still involved in development of neuropeptide Y. Neuropeptide Y (NPY) is a potent neurotransmitter in reproductive endocrine functions regulating stress, eating behavior, and metabolism. Considerable progress has been made in understanding the role of NPY and its receptors in various disorders. The synthesis of NPY antagonists is difficult, elusive, and a time consuming task.


Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/48

Neuropeptide Y Acetate Market Taxonomy

The global neuropeptide Y acetate market can be segmented on the basis of disease, application, and geography. On the basis of application, the global neuropeptide Y acetate market is classified into following categories - food intake, obesity, stress and diet, alcoholism, and receptors. The effect on food intake is due to its innervation with other appetite regulatory factors in the CNS. This results in regulating energy utilization via modulation of fat metabolism and deposition. NPY receptors (NPYRs) are distributed across the body, classified as NPYR1, NPYR2, and NPYR5, all of which are G protein coupled receptors. Besides, solid phase peptide synthesis, liquid phase peptide synthesis, and hybrid method are the different technologies used to synthesize these peptides.

Neuropeptide Y Acetate Market Dynamics

Increase in patient population suffering from metabolic disorders and cancer, rise in research and development pipeline of peptide drugs, and technological advancements are the major factors expected to propel growth of neuropeptide Y acetate market in the near future. However, complexity in peptide formulations and lack of regulatory standards pose a major challenge to the global market growth.

Neuropeptide Y Acetate Market – Drug in Use

Megestrol acetate is a synthetic, orally-active derivative of naturally occurring hormone porogesterone. It increases appetite via stimulation of neuropeptide. Megesterol acetate improves appetite as well as protein and energy intake. However, its adverse effects include dizziness, confusion, head-aches, hyperglycemia, diarrhea, thromboembolic phenomena, peripheral edema, break-through uterine bleeding, adrenal insufficiency, and adrenal suppression. It is majorly used in cachexia that occurs with a number of diseases such as advanced cancer, chronic heart failure, AIDS, rheumatoid arthritis, Crohn’s disease, chronic obstructive pulmonary disease, and renal failure. Nanocrystals of megestrol acetate can potentially address the unmet needs in treatment of anorexia-cachexia with improved bioavailability. The formulation may have the potential to produce a more rapid clinical response and significant improvements in the outcome of patients with this disorder.

Amgen, Inc., Phoenix Pharmaceuticals, Inc., Sigma Aldrich Corporation, Eli Lilly & Co, Pfizer, Inc., and Bachem Holding AG, Roche AG, Ipsen, Peptisyntha, Lonza, Inc., and Takeda Pharmaceuticals Company Limited are some of the key players in the global neuropeptide Y acetate market.

Get More Details about this Report@
https://www.coherentmarketinsights.com/ongoing-insight/neuropeptide-y-acetate-market-48

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuropeptide Y Acetate Market here

News-ID: 597231 • Views:

More Releases from Pharamceutical

Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo Ablation Therapy
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin 2 Receptor Blockers
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therapeutics market growth globally
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast

All 5 Releases


More Releases for NPY

Neuropeptide Y Acetate Market Vital Advantages to Boost Demand through 2026 With …
Neuropeptide Y (NPY), a peptide with 36-amino acids, acts as a neurotransmitter in the autonomic nervous system (ANS). It is one of the most abundant neuropeptides in the central and peripheral nervous system. In the periphery, NPY is widely distributed in the adrenal medulla, in the sympathetic nerves, platelets, and various cell types within white adipose tissue. NPY in the central nervous systems is found in highest concentration within the
Neuropeptide Y Acetate Market Healthcare Industry to Remain Key End-use; Vital A …
Neuropeptide Y (NPY), a peptide with 36-amino acids, acts as a neurotransmitter in the autonomic nervous system (ANS). It is one of the most abundant neuropeptides in the central and peripheral nervous system. In the periphery, NPY is widely distributed in the adrenal medulla, in the sympathetic nerves, platelets, and various cell types within white adipose tissue. NPY in the central nervous systems is found in highest concentration within the
Neuropeptide Y Receptor Type 2 in depth study and analysis published, 2017
Neuropeptide Y Receptor Type 2 Summary  Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity, Epilepsy, Type 1 Diabetes (Juvenile Diabetes) and
Precise Analysis on Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Cl …
The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with
Neuropeptide Y Acetate Market - Analysis And Forecast (2016-2024): Market Shares …
Neuropeptide Y (NPY), a peptide with 36-amino acids, acts as a neurotransmitter in the autonomic nervous system (ANS). It is one of the most abundant neuropeptides in the central and peripheral nervous system. In the periphery, NPY is widely distributed in the adrenal medulla, in the sympathetic nerves, platelets, and various cell types within white adipose tissue. NPY in the central nervous systems is found in highest concentration within the
NEUROPEPTIDE Y ACETATE MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND O …
Neuropeptide Y (NPY), a peptide with 36-amino acids, acts as a neurotransmitter in the autonomic nervous system (ANS). It is one of the most abundant neuropeptides in the central and peripheral nervous system. In the periphery, NPY is widely distributed in the adrenal medulla, in the sympathetic nerves, platelets, and various cell types within white adipose tissue. NPY in the central nervous systems is found in highest concentration within the